Deferiprone in Friedreich ataxia: a 6-month randomized controlled trial. - Wikidata - wikimedia - TriplyDB

Deferiprone in Friedreich ataxia: a 6-month randomized controlled trial.

Deferiprone in Friedreich ataxia: a 6-month randomized controlled trial.

http://www.wikidata.org/entity/Q53085750

about

Role of iron in neurodegenerative diseases.Pharmacological treatments for Friedreich ataxia.Metal Homeostasis Regulators Suppress FRDA Phenotypes in a Drosophila Model of the Disease Stable isotopes and LC-MS for monitoring metabolic disturbances in Friedreich's ataxia platelets.New developments and controversies in iron metabolism and iron chelation therapy.Abundance and Significance of Iron, Zinc, Copper, and Calcium in the Hearts of Patients With Friedreich Ataxia.Targeting mitochondrial metal dyshomeostasis for the treatment of neurodegeneration.Emerging therapies in Friedreich's ataxia.Friedreich Ataxia: current status and future prospects.Drosophila melanogaster Models of Metal-Related Human Diseases and Metal Toxicity.GIFT-1, a phase IIa clinical trial to test the safety and efficacy of IFNγ administration in FRDA patients.Cp/Heph mutant mice have iron-induced neurodegeneration diminished by deferiprone.Speciation in Metal Toxicity and Metal-Based Therapeutics.Friedreich's ataxia: clinical features, pathogenesis and management.Clinical Experience With Deferiprone Treatment for Friedreich Ataxia.Comprehensive systematic review summary: Treatment of cerebellar motor dysfunction and ataxia: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.Long-term treatment with thiamine as possible medical therapy for Friedreich ataxia.Drosophila melanogaster Models of Friedreich's Ataxia.Emerging therapeutics for the treatment of Friedreich’s ataxia

P2860

Q31038817-15C34E06-276A-4122-A69D-5083BB6F2182 Q34538823-4BAB1718-0798-4A25-BEDB-4EB806FC9E0B Q36081561-EED7C60C-C08C-4F3C-8A81-532FB53EB10F Q36207736-E668CEF8-2824-412E-AF1F-F127EEE5274D Q36719376-2CD4057E-A71F-4B5E-8B1C-3BF86B2F6A8B Q37018318-B8D17C7C-C764-48C7-9921-2A507C195832 Q38570991-04EC8FD3-7588-463F-837C-85619DE9D8E0 Q38648895-6E53F009-5473-4EC2-91BC-28ACD2C5A45C Q38730963-81A72298-8C0D-48A7-A1A5-60E162D47902 Q39419474-D835619E-F6EA-496F-975D-E94670D9D122 Q40128798-C861D5F9-D7E2-4668-B94F-04555C1A9C3B Q42423799-679D28E4-B72D-4F45-AD7F-95A19E2BC102 Q46737692-6B1F813D-633F-4757-BA9D-961AF9609E66 Q47623823-92DE35C2-649B-45E1-B24A-7095154A26A3 Q47786184-B1198A3B-ED77-4865-84EC-0B08EB96956C Q50026030-4BB98ED9-67D4-4C30-91BD-80C63F53D68E Q51595921-94E5933C-9EEA-49A4-A7D3-2214D3E103B3 Q55073764-7770DF79-0D55-4E12-B5E4-82A3C61D5B74 Q56700247-F7864CA5-4A76-46CF-AF66-B9C698AD9084

P2860

Deferiprone in Friedreich ataxia: a 6-month randomized controlled trial.

http://www.wikidata.org/entity/Q53085750

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh-hant

name

Deferiprone in Friedreich ataxia: a 6-month randomized controlled trial.

@en

Deferiprone in Friedreich ataxia: a 6-month randomized controlled trial.

@nl

type

label

Deferiprone in Friedreich ataxia: a 6-month randomized controlled trial.

@en

Deferiprone in Friedreich ataxia: a 6-month randomized controlled trial.

@nl

prefLabel

Deferiprone in Friedreich ataxia: a 6-month randomized controlled trial.

@en

Deferiprone in Friedreich ataxia: a 6-month randomized controlled trial.

@nl

P1433

Q53085750-3F2EBBBA-6A5B-4DE4-A611-0FB8593247EC

P1476

Q53085750-A7C620D7-9BD6-490F-907A-44F80F62E09B

P2093

Q53085750-04E05CCA-B42A-487B-980F-D03DF1CA2862

Q53085750-4341DDC1-145A-4E17-8B34-C1AD6594779A

Q53085750-43FB23C2-3A1C-4C0E-A368-0B7C6643D1C8

Q53085750-60825DB0-E3E4-4A15-90A4-263D2FA74C77

Q53085750-70CF1E90-0B9E-4FCF-80DA-F6D28B5568A8

Q53085750-739E7D1A-BC8C-43B6-8AF4-4090DF578C61

Q53085750-AD98F641-B1F8-493D-A138-DFC60AD1A9D0

Q53085750-CBA668A7-DAA1-45CA-84B8-281A003E23CB

Q53085750-CD2BA947-6DF9-46EF-8DFE-A741B35B7E66

Q53085750-EAE96835-E1B2-4FDB-AA40-06F9C27DD65D

P2860

Q53085750-0DB5764F-E09D-4205-A082-03D6ED24A1F8

Q53085750-0F9372A5-CBEB-447B-A72D-783272C0C90C

Q53085750-13532A14-4CF2-41F3-A359-D2056834FF52

Q53085750-13F5D17E-F38D-4607-8D80-402CBE0C8E45

Q53085750-2FEACCBA-A97B-4F49-9209-A46046F874EF

Q53085750-3877A608-F384-430C-9ECB-B8943EED46BF

Q53085750-3F526C9C-B438-48AC-A525-E7E0672A7223

Q53085750-50C76ED3-314F-4E2D-B0CC-50928206FBA8

Q53085750-52C8CC87-D9F0-4FE8-900A-A2A549D87247

Q53085750-5ABA4BE3-5448-472A-BD1D-4453363EFA43

P304

Q53085750-91E88429-9C19-4810-9A35-58B59E118A71

P31

Q53085750-56040E3E-6BF5-4C83-9C31-F3F33B6E3B37

P356

Q53085750-232DF1F1-8FE6-44C2-998B-C1CC543D55EF

P433

Q53085750-B9BE63C3-7913-41B0-8EA8-CCB2B556E5B3

P478

Q53085750-D3740613-5553-4AF9-8478-6E7A831096B3

P50

Q53085750-7225A8C2-794B-4F93-9052-EA4E63EA7499

Q53085750-D80B9FAA-2144-468A-9BDE-A06C095B769B

P577

Q53085750-C69F0369-2885-48FF-A43B-9E9B3E35712E

P698

Q53085750-9FA25EC4-40BF-4ADF-86D1-6B2F75FD5313

P356

P1433

Annals of Neurology

P1476

Deferiprone in Friedreich ataxia: a 6-month randomized controlled trial

@en

P2093

Arnold Munnich

http://www.w3.org/2001/XMLSchema#string

Caterina Mariotti

http://www.w3.org/2001/XMLSchema#string

Fernando Tricta

http://www.w3.org/2001/XMLSchema#string

Geneieve Tai

http://www.w3.org/2001/XMLSchema#string

Irene Sanz-Gallego

http://www.w3.org/2001/XMLSchema#string

Javier Arpa

http://www.w3.org/2001/XMLSchema#string

Mark A Tarnopolsky

http://www.w3.org/2001/XMLSchema#string

Martin B Delatycki

http://www.w3.org/2001/XMLSchema#string

Massimo Pandolfo

http://www.w3.org/2001/XMLSchema#string

Michael Spino

http://www.w3.org/2001/XMLSchema#string

P2860

Iron-dependent regulation of frataxin expression: implications for treatment of Friedreich ataxia

Prevalence gradients of Friedreich's ataxia and R1b haplotype in Europe co-localize, suggesting a common Palaeolithic origin in the Franco-Cantabrian ice age refuge

Human frataxin is an allosteric switch that activates the Fe-S cluster biosynthetic complex

Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes

Aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich ataxia

Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion

Pharmacological screening using an FXN-EGFP cellular genomic reporter assay for the therapy of Friedreich ataxia

Frataxin is essential for extramitochondrial Fe-S cluster proteins in mammalian tissues

Deferiprone targets aconitase: implication for Friedreich's ataxia treatment

Combined therapy with idebenone and deferiprone in patients with Friedreich's ataxia.

P304

509-521

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/ANA.24248

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

76

http://www.w3.org/2001/XMLSchema#string

P50

Kim-Hanh Le Quan Sang

P577

2014-08-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25112865

http://www.w3.org/2001/XMLSchema#string